US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

15.09

-13.3700-46.98%

Pre-market: 14.93-0.1600-1.06%05:37 EDT

Volume:19.75M

Turnover:262.99M

Market Cap:744.05M

PE:-4.08

High:15.79

Open:12.09

Low:11.36

Close:28.46

52wk High:35.83

52wk Low:11.36

Shares:49.31M

Float Shares:32.11M

Volume Ratio:32.00

T/O Rate:61.52%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.6975

EPS(LYR):-4.3239

ROE:-53.25%

ROA:-33.11%

PB:2.03

PE(LYR):-3.49

Loading ...

Overview Company News Filings

US Research Roundup-Allstate, Caribou Biosciences, Zscaler

ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22

ArriVent Biopharma price target lowered to $18 from $45 at Jefferies

Top Midday Decliners

MT Newswires Live

Why This Biotech Stock is Having Its Worst Day Ever

Analyst Maintains Buy on ArriVent Despite Trial Setback, Trims Price Target to $15 Ahead of Key ADC Data

ArriVent BioPharma Down over 52%, on Track for Record Low Close and Record Percent Decrease

Arrivent Biopharma, Inc. : Guggenheim Cuts Target Price to $18 from $45

THOMSON REUTERS

ArriVent says Phase 3 firmonertinib trial did not meet endpoint

ArriVent BioPharma's Lung Cancer Drug Fails to Meet Primary Endpoint in Phase 3 Trial

ArriVent Falls After Lung Cancer Drug Misses Late-Stage Trial Goal

Arrivent Biopharma Shares Down 62.4% Premarket After Co's Lung Cancer Therapy Fails Late-Stage Trial

THOMSON REUTERS

ArriVent's Lung Cancer Treatment Fails Late-Stage Trial

ArriVent Says Phase 3 Furvent Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion NSCLC Misses Primary PFS Endpoint

Arrivent Biopharma, Inc.: a Trend Toward an Improvement in Overall Survival was Also Observed

THOMSON REUTERS

Arrivent Biopharma - Furvent Phase 3 Trial of Firmonertinib Does not Meet Primary Endpoint of Pfs by Bicr

THOMSON REUTERS

Arrivent Biopharma - Confirmed Orr by Bicr 60% for Firmonertinib 240Mg, 33% for Control

THOMSON REUTERS

Arrivent Biopharma - Safety Profile in Furvent Consistent with Previous Studies, no New Safety Signals

THOMSON REUTERS

Arrivent Biopharma - Clinical Benefit Observed with Secondary Endpoints Including Pfs and Confirmed Orr

THOMSON REUTERS

Arrivent Announces Program Update from the Phase 3 Furvent Trial of Firmonertinib in First-Line Egfr Exon 20 Insertion Mutant Nsclc

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sgp.itiger.com/stock/AVBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":15.09,"timestamp":1791316800000,"preClose":28.46,"halted":0,"volume":19752235,"hourTrading":{"tag":"盘前","latestPrice":14.93,"preClose":15.09,"latestTime":"05:37 EDT","volume":2922,"amount":43170.045846,"timestamp":1791365856732,"change":-0.16,"changeRate":-0.010603,"amplitude":0.031127},"delay":0,"changeRate":-0.4697821503865074,"floatShares":32106300,"shares":49307729,"eps":-3.697539,"marketStatus":"Pre-Mkt","change":-13.37,"latestTime":"10-07 05:38:03 EDT","open":12.09,"high":15.79,"low":11.36,"amount":262990797.119505,"amplitude":0.155657,"askPrice":16.27,"askSize":100,"bidPrice":14.5,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-3.697539,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791379800000},"marketStatusCode":1,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":15.09,"preHourTrading":{"tag":"盘前","latestPrice":14.93,"preClose":15.09,"latestTime":"05:37 EDT","volume":2922,"amount":43170.045846,"timestamp":1791365856732,"change":-0.16,"changeRate":-0.010603,"amplitude":0.031127},"postHourTrading":{"tag":"盘后","latestPrice":14.9353,"preClose":15.09,"latestTime":"19:59 EDT","volume":44513,"amount":664290.4969,"timestamp":1791331195934,"change":-0.1547,"changeRate":-0.010252,"amplitude":0.035785},"volumeRatio":31.996669167965994,"optionData":{"bulkOrders":[{"symbol":"AVBP","call":true,"expireDate":1792123200000,"strike":"25.0","timestamp":1791303453054,"price":0.05,"volume":2000,"amount":10000,"type":"*"},{"symbol":"AVBP","call":true,"expireDate":1792123200000,"strike":"20.0","timestamp":1791303453054,"price":0.06,"volume":2000,"amount":12000,"type":"-"}]},"impliedVol":1.0485,"impliedVolPercentile":0.328},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","floatShares":32106300,"roa":"-33.11%","roe":"-53.25%","lyrEps":-4.323888,"volumeRatio":31.996669167965994,"shares":49307729,"dividePrice":0,"high":15.79,"amplitude":0.155657,"preClose":28.46,"low":11.36,"week52Low":11.36,"pbRate":"2.03","week52High":35.83,"institutionHeld":0,"latestPrice":15.09,"committee":0.333333,"eps":-3.697539,"divideRate":0,"volume":19752235,"delay":0,"ttmEps":-3.697539,"open":12.09,"prevYearClose":20.12,"prevWeekClose":28.27,"prevMonthClose":30.28,"prevQuarterClose":30.28,"fiveDayClose":29.54,"twentyDayClose":30.28,"sixtyDayClose":33.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"AVBP","fiscalQuarterEnding":"2026/06","expectedEps":-0.98,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.05},{"market":"US","date":"2026-05-11","symbol":"AVBP","fiscalQuarterEnding":"2026/03","expectedEps":-0.88,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-0.96},{"market":"US","date":"2026-03-05","symbol":"AVBP","fiscalQuarterEnding":"2025/12","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2025-11-10","symbol":"AVBP","fiscalQuarterEnding":"2025/09","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.83},{"market":"US","date":"2025-08-11","symbol":"AVBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.7,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":-0.9}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1766462400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVBP","date":"2026-10-05","current":-4.081093,"percent":0.494656,"low":-15.980041,"twenty":-10.960617,"median":-8.452954,"eighty":-6.06248,"high":-4.80343,"avg":-8.593266,"sd":2.426123,"marketCap":1393929498},"quantilePoints":[{"date":"2024-01-26","current":-15.452095,"twenty":-15.452095,"median":-15.452095,"eighty":-15.452095,"marketCap":905214654},{"date":"2024-02-02","current":-11.990156,"twenty":-12.001066,"median":-11.872873,"eighty":-10.91006,"marketCap":702407320},{"date":"2024-02-09","current":-12.548731,"twenty":-12.548731,"median":-12.001066,"eighty":-11.75559,"marketCap":735129780},{"date":"2024-02-16","current":-12.588659,"twenty":-12.548731,"median":-12.126596,"eighty":-11.919241,"marketCap":737468829},{"date":"2024-02-23","current":-11.219707,"twenty":-12.556717,"median":-11.998256,"eighty":-11.67237,"marketCap":657272853},{"date":"2024-03-01","current":-12.286349,"twenty":-12.548731,"median":-11.990156,"eighty":-11.204877,"marketCap":719758884},{"date":"2024-03-08","current":-11.464977,"twenty":-12.548731,"median":-11.964074,"eighty":-11.315533,"marketCap":671641299},{"date":"2024-03-15","current":-10.59227,"twenty":-12.5031,"median":-11.767288,"eighty":-11.121598,"marketCap":620516364},{"date":"2024-03-22","current":-10.386927,"twenty":-12.327418,"median":-11.658912,"eighty":-10.920492,"marketCap":608486967},{"date":"2024-03-28","current":-10.267144,"twenty":-12.279504,"median":-11.507757,"eighty":-10.718898,"marketCap":601469820},{"date":"2024-04-05","current":-8.84046,"twenty":-12.261251,"median":-11.265338,"eighty":-10.410884,"marketCap":612935625},{"date":"2024-04-12","current":-8.536116,"twenty":-12.10149,"median":-11.165519,"eighty":-9.961411,"marketCap":591834562},{"date":"2024-04-19","current":-7.487821,"twenty":-11.997694,"median":-11.025772,"eighty":-8.805678,"marketCap":519153125},{"date":"2024-04-26","current":-7.507145,"twenty":-11.992272,"median":-10.91658,"eighty":-8.501334,"marketCap":520492875},{"date":"2024-05-03","current":-8.115832,"twenty":-11.986485,"median":-10.803317,"eighty":-8.191193,"marketCap":562695000},{"date":"2024-05-10","current":-8.079495,"twenty":-11.960082,"median":-10.543786,"eighty":-8.115832,"marketCap":602552562},{"date":"2024-05-17","current":-9.049573,"twenty":-11.929189,"median":-10.386927,"eighty":-8.101297,"marketCap":674899062},{"date":"2024-05-24","current":-8.479203,"twenty":-11.828069,"median":-10.210104,"eighty":-8.115832,"marketCap":632362000},{"date":"2024-05-31","current":-8.739687,"twenty":-11.762609,"median":-9.361752,"eighty":-8.133223,"marketCap":651788375},{"date":"2024-06-07","current":-8.241175,"twenty":-11.7192,"median":-8.959751,"eighty":-8.180566,"marketCap":614610312},{"date":"2024-06-14","current":-8.456747,"twenty":-11.662334,"median":-8.912923,"eighty":-8.216398,"marketCap":630687312},{"date":"2024-06-21","current":-7.455231,"twenty":-11.653208,"median":-8.84046,"eighty":-8.15931,"marketCap":555996250},{"date":"2024-06-28","current":-7.81452,"twenty":-11.61214,"median":-8.79358,"eighty":-8.133223,"marketCap":582791250},{"date":"2024-07-05","current":-8.205246,"twenty":-11.533425,"median":-8.753505,"eighty":-8.152944,"marketCap":611930812},{"date":"2024-07-12","current":-8.268121,"twenty":-11.43988,"median":-8.706383,"eighty":-8.152944,"marketCap":616619937},{"date":"2024-07-15","current":-8.259139,"twenty":-11.414782,"median":-8.695535,"eighty":-8.154535,"marketCap":615950062},{"date":"2024-08-02","current":-9.655872,"twenty":-11.389685,"median":-8.706383,"eighty":-8.156127,"marketCap":720115625},{"date":"2024-08-09","current":-10.262171,"twenty":-11.294999,"median":-8.753505,"eighty":-8.186872,"marketCap":765332187},{"date":"2024-08-16","current":-10.701201,"twenty":-11.237959,"median":-8.81702,"eighty":-8.205246,"marketCap":801359406},{"date":"2024-08-23","current":-10.705686,"twenty":-11.199173,"median":-8.912923,"eighty":-8.209568,"marketCap":801695265},{"date":"2024-08-30","current":-12.010819,"twenty":-11.389685,"median":-8.993434,"eighty":-8.224295,"marketCap":899430214},{"date":"2024-09-06","current":-11.93009,"twenty":-11.657877,"median":-9.253918,"eighty":-8.235785,"marketCap":893384753},{"date":"2024-09-13","current":-10.669806,"twenty":-11.694732,"median":-9.655872,"eighty":-8.248361,"marketCap":799008394},{"date":"2024-09-20","current":-10.85369,"twenty":-11.663166,"median":-9.763659,"eighty":-8.262732,"marketCap":812778610},{"date":"2024-09-27","current":-10.544226,"twenty":-11.657877,"median":-10.060071,"eighty":-8.269917,"marketCap":789604344},{"date":"2024-10-04","current":-11.49056,"twenty":-11.61214,"median":-10.208101,"eighty":-8.279798,"marketCap":860470578},{"date":"2024-10-11","current":-12.463804,"twenty":-11.739278,"median":-10.315491,"eighty":-8.299559,"marketCap":933351966},{"date":"2024-10-18","current":-13.002004,"twenty":-11.938503,"median":-10.371883,"eighty":-8.317243,"marketCap":973655038},{"date":"2024-10-25","current":-13.912458,"twenty":-11.99333,"median":-10.426855,"eighty":-8.325491,"marketCap":1041834400},{"date":"2024-10-31","current":-14.114283,"twenty":-12.114871,"median":-10.539741,"eighty":-8.328911,"marketCap":1056948052},{"date":"2024-11-08","current":-15.980041,"twenty":-12.249611,"median":-10.573379,"eighty":-8.330997,"marketCap":1196665367},{"date":"2024-11-15","current":-11.674764,"twenty":-12.282511,"median":-10.59227,"eighty":-8.332793,"marketCap":946216280},{"date":"2024-11-22","current":-11.05527,"twenty":-12.272349,"median":-10.669806,"eighty":-8.342492,"marketCap":896007510},{"date":"2024-11-29","current":-12.456408,"twenty":-12.274941,"median":-10.685503,"eighty":-8.352544,"marketCap":1009566943},{"date":"2024-12-06","current":-11.870175,"twenty":-12.284404,"median":-10.712096,"eighty":-8.353452,"marketCap":962053946},{"date":"2024-12-13","current":-10.760075,"twenty":-12.274941,"median":-10.748293,"eighty":-8.371867,"marketCap":872082526},{"date":"2024-12-20","current":-10.664448,"twenty":-12.261979,"median":-10.759506,"eighty":-8.380399,"marketCap":864332179},{"date":"2024-12-27","current":-11.46688,"twenty":-12.254096,"median":-10.803317,"eighty":-8.380399,"marketCap":929367700},{"date":"2025-01-03","current":-11.421146,"twenty":-12.244582,"median":-10.85369,"eighty":-8.380399,"marketCap":925661012},{"date":"2025-01-10","current":-11.167527,"twenty":-12.234172,"median":-10.860965,"eighty":-8.382195,"marketCap":905105744},{"date":"2025-01-17","current":-10.177999,"twenty":-12.217129,"median":-10.850538,"eighty":-8.390279,"marketCap":824906501},{"date":"2025-01-24","current":-11.329677,"twenty":-12.196013,"median":-10.850538,"eighty":-8.405549,"marketCap":918247637},{"date":"2025-01-31","current":-12.09469,"twenty":-12.164539,"median":-10.860965,"eighty":-8.437266,"marketCap":980250413},{"date":"2025-02-07","current":-11.383727,"twenty":-12.161213,"median":-10.897572,"eighty":-8.450678,"marketCap":922628268},{"date":"2025-02-14","current":-11.16337,"twenty":-12.157147,"median":-10.9231,"eighty":-8.461238,"marketCap":904768772},{"date":"2025-02-21","current":-11.387884,"twenty":-12.140884,"median":-10.92545,"eighty":-8.479203,"marketCap":922965239},{"date":"2025-02-28","current":-9.8537,"twenty":-12.107163,"median":-10.91658,"eighty":-8.519623,"marketCap":798622715},{"date":"2025-03-07","current":-9.217439,"twenty":-12.09469,"median":-10.885085,"eighty":-8.536116,"marketCap":741893256},{"date":"2025-03-14","current":-9.192082,"twenty":-12.065586,"median":-10.857328,"eighty":-8.618427,"marketCap":739852284},{"date":"2025-03-21","current":-8.258082,"twenty":-12.010819,"median":-10.847386,"eighty":-8.519623,"marketCap":664676489},{"date":"2025-03-28","current":-7.848136,"twenty":-12.001066,"median":-10.781696,"eighty":-8.449161,"marketCap":631680778},{"date":"2025-04-04","current":-7.159258,"twenty":-11.995446,"median":-10.737081,"eighty":-8.380399,"marketCap":576234377},{"date":"2025-04-11","current":-7.125448,"twenty":-11.990156,"median":-10.711139,"eighty":-8.353452,"marketCap":573513081},{"date":"2025-04-17","current":-7.564978,"twenty":-11.988746,"median":-10.703443,"eighty":-8.330997,"marketCap":608889926},{"date":"2025-04-25","current":-8.94696,"twenty":-11.984909,"median":-10.669806,"eighty":-8.330476,"marketCap":720122890},{"date":"2025-05-02","current":-8.908923,"twenty":-11.976101,"median":-10.6604,"eighty":-8.330997,"marketCap":717061432},{"date":"2025-05-09","current":-8.353948,"twenty":-11.95416,"median":-10.580862,"eighty":-8.330997,"marketCap":672392561},{"date":"2025-05-16","current":-5.164444,"twenty":-11.945123,"median":-10.566696,"eighty":-8.323142,"marketCap":658249673},{"date":"2025-05-23","current":-5.537551,"twenty":-11.932894,"median":-10.539741,"eighty":-8.281274,"marketCap":705805133},{"date":"2025-05-30","current":-5.636867,"twenty":-11.923581,"median":-10.506711,"eighty":-8.258716,"marketCap":718463781},{"date":"2025-06-06","current":-6.29987,"twenty":-11.889801,"median":-10.45834,"eighty":-8.241176,"marketCap":802968806},{"date":"2025-06-13","current":-6.342817,"twenty":-11.86768,"median":-10.37894,"eighty":-8.205246,"marketCap":808442816},{"date":"2025-06-20","current":-6.681029,"twenty":-11.831093,"median":-10.360937,"eighty":-8.13004,"marketCap":851550643},{"date":"2025-06-27","current":-6.122711,"twenty":-11.774139,"median":-10.336565,"eighty":-8.056606,"marketCap":780388516},{"date":"2025-07-03","current":-5.951741,"twenty":-11.764948,"median":-10.291317,"eighty":-8.012114,"marketCap":758596999},{"date":"2025-07-11","current":-6.3128,"twenty":-11.752729,"median":-10.177999,"eighty":-7.877518,"marketCap":804616846},{"date":"2025-07-18","current":-6.510523,"twenty":-11.737545,"median":-10.15098,"eighty":-7.814365,"marketCap":829818191},{"date":"2025-07-25","current":-6.146598,"twenty":-11.721024,"median":-10.060071,"eighty":-7.74746,"marketCap":783433107},{"date":"2025-08-01","current":-5.590682,"twenty":-11.706801,"median":-9.819907,"eighty":-7.667253,"marketCap":712577152},{"date":"2025-08-08","current":-5.312724,"twenty":-11.672734,"median":-9.759167,"eighty":-7.57343,"marketCap":677149175},{"date":"2025-08-15","current":-5.522288,"twenty":-11.663891,"median":-9.64689,"eighty":-7.464633,"marketCap":755393737},{"date":"2025-08-22","current":-5.895976,"twenty":-11.659587,"median":-9.496371,"eighty":-7.205647,"marketCap":806510606},{"date":"2025-08-29","current":-5.697269,"twenty":-11.653822,"median":-9.38434,"eighty":-6.898922,"marketCap":779329414},{"date":"2025-09-05","current":-5.789208,"twenty":-11.653208,"median":-9.260758,"eighty":-6.705187,"marketCap":791905786},{"date":"2025-09-12","current":-5.640919,"twenty":-11.550537,"median":-9.192082,"eighty":-6.342817,"marketCap":771621314},{"date":"2025-09-19","current":-5.510425,"twenty":-11.49056,"median":-9.038346,"eighty":-6.3128,"marketCap":753770979},{"date":"2025-09-26","current":-5.092249,"twenty":-11.46688,"median":-8.984996,"eighty":-6.266951,"marketCap":696568768},{"date":"2025-10-03","current":-5.584569,"twenty":-11.464977,"median":-8.939882,"eighty":-6.203238,"marketCap":763913215},{"date":"2025-10-10","current":-6.266699,"twenty":-11.458565,"median":-8.908923,"eighty":-6.178119,"marketCap":857221786},{"date":"2025-10-17","current":-5.820349,"twenty":-11.441934,"median":-8.860202,"eighty":-6.17476,"marketCap":796165526},{"date":"2025-10-24","current":-5.365101,"twenty":-11.433619,"median":-8.84046,"eighty":-6.120027,"marketCap":733892196},{"date":"2025-10-31","current":-5.477801,"twenty":-11.433619,"median":-8.796928,"eighty":-6.098553,"marketCap":749308395},{"date":"2025-11-07","current":-5.454075,"twenty":-11.421146,"median":-8.757651,"eighty":-5.987916,"marketCap":746062880},{"date":"2025-11-14","current":-5.38103,"twenty":-11.41283,"median":-8.728459,"eighty":-5.931566,"marketCap":812417184},{"date":"2025-11-21","current":-5.484932,"twenty":-11.400357,"median":-8.689159,"eighty":-5.895976,"marketCap":828104101},{"date":"2025-11-28","current":-6.2724,"twenty":-11.397031,"median":-8.627903,"eighty":-5.884113,"marketCap":946994421},{"date":"2025-12-05","current":-6.657931,"twenty":-11.389547,"median":-8.556032,"eighty":-5.884113,"marketCap":1005201140},{"date":"2025-12-12","current":-6.649728,"twenty":-11.384558,"median":-8.523142,"eighty":-5.893603,"marketCap":1003962699},{"date":"2025-12-19","current":-5.788435,"twenty":-11.375905,"median":-8.467975,"eighty":-5.893603,"marketCap":873926412},{"date":"2025-12-26","current":-6.094673,"twenty":-11.359859,"median":-8.441726,"eighty":-5.901564,"marketCap":920161536},{"date":"2026-01-02","current":-5.501338,"twenty":-11.346075,"median":-8.391627,"eighty":-5.884113,"marketCap":830580983},{"date":"2026-01-09","current":-5.364625,"twenty":-11.337228,"median":-8.380399,"eighty":-5.844354,"marketCap":809940302},{"date":"2026-01-16","current":-5.988037,"twenty":-11.332171,"median":-8.373482,"eighty":-5.835858,"marketCap":904061805},{"date":"2026-01-23","current":-6.890344,"twenty":-11.326351,"median":-8.3537,"eighty":-5.833294,"marketCap":1040290297},{"date":"2026-01-30","current":-6.152093,"twenty":-11.304731,"median":-8.339979,"eighty":-5.843953,"marketCap":928830622},{"date":"2026-02-06","current":-5.837652,"twenty":-11.270243,"median":-8.329694,"eighty":-5.843953,"marketCap":881357057},{"date":"2026-02-13","current":-6.130218,"twenty":-11.263238,"median":-8.321475,"eighty":-5.843953,"marketCap":925528113},{"date":"2026-02-20","current":-6.313414,"twenty":-11.254838,"median":-8.290577,"eighty":-5.845558,"marketCap":953186625},{"date":"2026-02-27","current":-6.351694,"twenty":-11.246523,"median":-8.270367,"eighty":-5.848589,"marketCap":958966016},{"date":"2026-03-06","current":-6.710988,"twenty":-11.219707,"median":-8.258082,"eighty":-5.878182,"marketCap":1116090955},{"date":"2026-03-13","current":-6.40401,"twenty":-11.204946,"median":-8.245403,"eighty":-5.8814,"marketCap":1065038082},{"date":"2026-03-20","current":-6.07577,"twenty":-11.192473,"median":-8.232192,"eighty":-5.884113,"marketCap":1010449078},{"date":"2026-03-27","current":-5.79537,"twenty":-11.188316,"median":-8.205246,"eighty":-5.878182,"marketCap":963816367},{"date":"2026-04-02","current":-6.437233,"twenty":-11.18605,"median":-8.155331,"eighty":-5.851728,"marketCap":1070563284},{"date":"2026-04-10","current":-7.242551,"twenty":-11.184423,"median":-8.115832,"eighty":-5.873048,"marketCap":1204494199},{"date":"2026-04-17","current":-7.869796,"twenty":-11.184158,"median":-8.05762,"eighty":-5.880756,"marketCap":1308810027},{"date":"2026-04-24","current":-8.239233,"twenty":-11.170853,"median":-8.079495,"eighty":-5.88357,"marketCap":1370250282},{"date":"2026-05-01","current":-8.263153,"twenty":-11.164201,"median":-8.071094,"eighty":-5.884113,"marketCap":1374228427},{"date":"2026-05-08","current":-8.043687,"twenty":-11.160044,"median":-8.062693,"eighty":-5.892853,"marketCap":1337729551},{"date":"2026-05-15","current":-9.113539,"twenty":-11.148286,"median":-8.082287,"eighty":-5.895788,"marketCap":1323659453},{"date":"2026-05-22","current":-8.658182,"twenty":-11.130931,"median":-8.115832,"eighty":-5.903426,"marketCap":1257523056},{"date":"2026-05-29","current":-8.648562,"twenty":-11.121131,"median":-8.15931,"eighty":-5.909002,"marketCap":1256125808},{"date":"2026-06-05","current":-10.611083,"twenty":-11.112406,"median":-8.208286,"eighty":-5.914633,"marketCap":1541164367},{"date":"2026-06-12","current":-9.684337,"twenty":-11.089363,"median":-8.224914,"eighty":-5.923855,"marketCap":1406562825},{"date":"2026-06-18","current":-10.056318,"twenty":-11.074395,"median":-8.233917,"eighty":-5.929786,"marketCap":1460589742},{"date":"2026-06-26","current":-10.846778,"twenty":-11.071901,"median":-8.241176,"eighty":-5.939636,"marketCap":1575396939},{"date":"2026-07-02","current":-11.063233,"twenty":-11.071901,"median":-8.253856,"eighty":-5.951741,"marketCap":1606835016},{"date":"2026-07-10","current":-10.797074,"twenty":-11.071901,"median":-8.258372,"eighty":-5.954231,"marketCap":1568177825},{"date":"2026-07-17","current":-10.505261,"twenty":-11.071901,"median":-8.265637,"eighty":-5.966771,"marketCap":1525794641},{"date":"2026-07-24","current":-10.11404,"twenty":-11.070167,"median":-8.283439,"eighty":-5.979263,"marketCap":1468973229},{"date":"2026-07-31","current":-9.831847,"twenty":-11.063233,"median":-8.313032,"eighty":-5.987916,"marketCap":1427987292},{"date":"2026-08-07","current":-9.944083,"twenty":-11.060026,"median":-8.325975,"eighty":-5.988037,"marketCap":1444288517},{"date":"2026-08-14","current":-9.008172,"twenty":-11.059428,"median":-8.330997,"eighty":-5.993847,"marketCap":1479231870},{"date":"2026-08-21","current":-8.761948,"twenty":-11.05527,"median":-8.347715,"eighty":-5.99759,"marketCap":1438799532},{"date":"2026-08-28","current":-9.308444,"twenty":-11.025772,"median":-8.353948,"eighty":-6.007177,"marketCap":1528539599},{"date":"2026-09-04","current":-9.317452,"twenty":-11.021545,"median":-8.377748,"eighty":-6.007177,"marketCap":1530018830},{"date":"2026-09-11","current":-8.617818,"twenty":-11.020363,"median":-8.380399,"eighty":-6.015927,"marketCap":1415131822},{"date":"2026-09-18","current":-8.515725,"twenty":-11.011642,"median":-8.38489,"eighty":-6.022488,"marketCap":1398367194},{"date":"2026-09-25","current":-9.038199,"twenty":-11.006851,"median":-8.398491,"eighty":-6.041944,"marketCap":1484162642},{"date":"2026-10-02","current":-8.68688,"twenty":-10.96973,"median":-8.449161,"eighty":-6.059291,"marketCap":1426472599},{"date":"2026-10-05","current":-8.4887,"twenty":-10.960617,"median":-8.452954,"eighty":-6.06248,"marketCap":1393929498}],"updateTime":1791352904549},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673009523","title":"US Research Roundup-Allstate, Caribou Biosciences, Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2673009523","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673009523?lang=en_us&edition=fundamental","pubTime":"2026-10-07 15:36","pubTimestamp":1791358582,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, ZscalerOct 7 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Allstate Cor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nL4N45T0H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ISPR","FERG","DX","FINX","NLY","09711","MDU","VDE","ODDZ","MAS","CIM","FLUT","COP","HE","TRUN","CRDT","FAF","ALLY","LOB","NSLR","AMBQ","AXP","IBP","CNM","MHK","MIAX","COIO","MRVL","IPAY","GILD","AGNC","EFC","CME","BPAY","FBIN","EXEL","SOXY","ADAM","COIN","MFA","BLDR","ICE","LW","ALL","COF","ZS","FNF","CACC","CBOE","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673063538","title":"ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2673063538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673063538?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:55","pubTimestamp":1791316530,"startTime":"0","endTime":"0","summary":"Analyst Boris Peaker from JonesTrading reiterated a Buy rating on ArriVent BioPharma, Inc. and decreased the price target to $22.00 from $45.00. Bo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-retains-buy-rating-as-analyst-sees-upside-from-broader-pipeline-despite-trial-miss-cutting-price-target-to-22-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-retains-buy-rating-as-analyst-sees-upside-from-broader-pipeline-despite-trial-miss-cutting-price-target-to-22-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068914","title":"ArriVent Biopharma price target lowered to $18 from $45 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068914?lang=en_us&edition=fundamental","pubTime":"2026-10-07 02:25","pubTimestamp":1791311118,"startTime":"0","endTime":"0","summary":"Jefferies lowered the firm’s price target on ArriVent Biopharma (AVBP) to $18 from $45 and keeps a Buy rating on the shares after the company annou...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-price-target-lowered-to-18-from-45-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-price-target-lowered-to-18-from-45-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673685530","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2673685530","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673685530?lang=en_us&edition=fundamental","pubTime":"2026-10-07 02:19","pubTimestamp":1791310749,"startTime":"0","endTime":"0","summary":"Seagate Technology  and Toshiba are competing to acquire TDK's magnetic-head business for hard-disk drives in a deal that could be worth several billion dollars, Bloomberg reported, citing people familiar with the matter.Shares declined 9.5%, with intraday trading volume rising to over 5.2 million from a daily average of about 4.6 million.ArriVent BioPharma  said its phase 3 trial of firmonertinib did not achieve its primary progression-free survival goal in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer.Shares sank 48% as intraday trading volume soared to over 14.1 million from a daily average of roughly 525,000.NFT  shares slumped 70% after the company priced a direct offering to raise around $2.55 million.Intraday trading volume was over 4.6 million shares, versus a daily average of about 2.7 million.Price: 804.50, Change: -82.59, Percent Change: -9.31","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRMY","QQQG","IE00B19Z9Z06.USD","LU1670628061.USD","STXL","BK4512","BK4170","STX","LU0203345920.USD","QQQA","TTDKF","BK4585","DISK","IE00B894F039.SGD","LU1670627923.USD","STXU","BK4139","BK4077","MI","LU1983260115.SGD","AVBP","BK4588","LU0203347892.USD","BK4148","RULE","FCUS","IE00B19Z9P08.USD","STXX","EGGY","WLDR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673604057","title":"Why This Biotech Stock is Having Its Worst Day Ever","url":"https://stock-news.laohu8.com/highlight/detail?id=2673604057","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673604057?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:53","pubTimestamp":1791301980,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma stock declined sharply on Tuesday after the biopharmaceutical company published disappointing results for its lung-cancer drug.Shares of ArriVent BioPharma plunged 54% to $13, on pa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4585","BK4588","BK4139","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673605730","title":"Analyst Maintains Buy on ArriVent Despite Trial Setback, Trims Price Target to $15 Ahead of Key ADC Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2673605730","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673605730?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:35","pubTimestamp":1791300918,"startTime":"0","endTime":"0","summary":"Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on ArriVent BioPharma, Inc.. The associated price target was lowered to $15...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-arrivent-despite-trial-setback-trims-price-target-to-15-ahead-of-key-adc-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-arrivent-despite-trial-setback-trims-price-target-to-15-ahead-of-key-adc-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673052419","title":"ArriVent BioPharma Down over 52%, on Track for Record Low Close and Record Percent Decrease","url":"https://stock-news.laohu8.com/highlight/detail?id=2673052419","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673052419?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:07","pubTimestamp":1791299220,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc.  is currently at $13.49, down $14.97 or 52.61%--Would be new all-time closing low --Would be largest percent decrease on record --Currently down three of the past four days--Down 32.97% year-to-date; on pace for worst year on record --Down 62.15% from its all-time closing high of $35.63 on Nov. 7, 2024--Down 30.16% from 52 weeks ago , when it closed at $19.31--Down 61.18% from its 52-week closing high of $34.74 on June 30, 2026--Would be a new 52-week closing low--Traded as low as $11.36; new all-time intraday low --Down 60.08% at today's intraday low; largest intraday percent decrease on record All data as of 11:05:10 AM ETSource: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673524500","title":"Arrivent Biopharma, Inc. : Guggenheim Cuts Target Price to $18 from $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2673524500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673524500?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:06","pubTimestamp":1791299211,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nFWN45S1L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051961","title":"ArriVent says Phase 3 firmonertinib trial did not meet endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051961","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051961?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:13","pubTimestamp":1791292413,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) announced that the FURVENT Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, loca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL","AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673059400","title":"ArriVent BioPharma's Lung Cancer Drug Fails to Meet Primary Endpoint in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673059400","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673059400?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:52","pubTimestamp":1791291120,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma said a treatment it's developing for a type of lung cancer failed to meet the primary endpoint in a Phase 3 trial.The stock slid 59% to $11.77 in premarket trading on Tuesday. At Mo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"ArriVent BioPharma's Lung Cancer Drug Fails to Meet Primary Endpoint in Phase 3 Trial","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673931059","title":"ArriVent Falls After Lung Cancer Drug Misses Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673931059","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673931059?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:40","pubTimestamp":1791290420,"startTime":"0","endTime":"0","summary":"BUZZ-ArriVent falls after lung cancer drug misses late-stage trial goal** Shares of drug developer ArriVent BioPharmaAVBP.Ofall 62.7% to $10.62 premarket** Co says its experimental drug firmonertinibf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL4N45S0VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673605954","title":"Arrivent Biopharma Shares Down 62.4% Premarket After Co's Lung Cancer Therapy Fails Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673605954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673605954?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:36","pubTimestamp":1791290211,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nFWN45R1M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056964","title":"ArriVent's Lung Cancer Treatment Fails Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056964","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056964?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:07","pubTimestamp":1791288455,"startTime":"0","endTime":"0","summary":"ArriVent's lung cancer treatment fails late-stage trialOct 6 (Reuters)-ArriVent BioPharmaAVBP.Osaid on Tuesday its therapy to treat patients with a type of lung cancer did not meet the main goal in a late-stage trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL4N45S0TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056995","title":"ArriVent Says Phase 3 Furvent Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion NSCLC Misses Primary PFS Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056995","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056995?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:07","pubTimestamp":1791288439,"startTime":"0","endTime":"0","summary":"ArriVent says Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC misses primary PFS endpointArriVent reported its Phase 3 FURVENT trial of firmonertinib in first-line EG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDLbyN8Kn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","AVBP","IE00BQXX3F31.USD","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","NDAQ","BK4585","SG9999014005.SGD","BK4139","BK4112","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705636","title":"Arrivent Biopharma, Inc.: a Trend Toward an Improvement in Overall Survival was Also Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705636?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA87SF6V:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673568190","title":"Arrivent Biopharma - Furvent Phase 3 Trial of Firmonertinib Does not Meet Primary Endpoint of Pfs by Bicr","url":"https://stock-news.laohu8.com/highlight/detail?id=2673568190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673568190?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA87SF6V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673305681","title":"Arrivent Biopharma - Confirmed Orr by Bicr 60% for Firmonertinib 240Mg, 33% for Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2673305681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673305681?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA87SF6V:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056883","title":"Arrivent Biopharma - Safety Profile in Furvent Consistent with Previous Studies, no New Safety Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056883?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA87SF6V:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056854","title":"Arrivent Biopharma - Clinical Benefit Observed with Secondary Endpoints Including Pfs and Confirmed Orr","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056854?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA87SF6V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055000","title":"Arrivent Announces Program Update from the Phase 3 Furvent Trial of Firmonertinib in First-Line Egfr Exon 20 Insertion Mutant Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055000?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA87SF6V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}]}}